BACKGROUND: There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate, a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC. METHOD: Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed. RESULTS: Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c-kit and PDGFR-alpha. CONCLUSION: We observed an unexpected high progression rate of metastatic ACC within short periods during imatinib treatment. Use of imatinib to treat cancers without c-kit or PDGFR-alpha mutation should be approached with caution. (c) 2005 Wiley Periodicals, Inc.
BACKGROUND: There is a lack of effective treatment for metastatic adenoid cystic carcinoma (ACC), a usually indolent tumor. We studied the efficacy of imatinib mesylate, a potent inhibitor of KIT tyrosine kinase, in patients with KIT-positive metastatic ACC. METHOD: Five patients with lung metastasis were treated in a pilot study with imatinib 400 mg by mouth twice a day. Mutations of c-kit and platelet-derived growth factor receptor (PDGFR)-alpha in tumors from these patients were analyzed. RESULTS: Disease progression was noted in three of five patients during the short treatment periods, ranging from 2 to 3 weeks. Three patients died of disease within 6 months. No detectable mutations were found in c-kit and PDGFR-alpha. CONCLUSION: We observed an unexpected high progression rate of metastatic ACC within short periods during imatinib treatment. Use of imatinib to treat cancers without c-kit or PDGFR-alpha mutation should be approached with caution. (c) 2005 Wiley Periodicals, Inc.
Authors: Anjali K Gupta; Werner W Wilke; Erin N Taylor; Kellie L Bodeker; Henry T Hoffman; Mohammed M Milhem; John M Buatti; Robert A Robinson Journal: Cancer Biol Ther Date: 2009-10-22 Impact factor: 4.742
Authors: Danyel Elias da Cruz Perez; José Magrin; Oslei Paes de Almeida; Luiz Paulo Kowalski Journal: Pathol Oncol Res Date: 2007-07-03 Impact factor: 3.201
Authors: Daniel Wetterskog; Paul M Wilkerson; Daniel N Rodrigues; Maryou B Lambros; Karen Fritchie; Mattias K Andersson; Rachael Natrajan; Arnaud Gauthier; Silvana Di Palma; Sami Shousha; Zoran Gatalica; Chantal Töpfer; Vesna Vukovic; Roger A'Hern; Britta Weigelt; Anne Vincent-Salomon; Göran Stenman; Brian P Rubin; Jorge S Reis-Filho Journal: Histopathology Date: 2013-02-12 Impact factor: 5.087